Cystic Fibrosis Foundation distributed the following clinical trial updates during the month of October. Click the trial title to get more details.
The following alerts were distributed on October 13th:
Cohorts 1 and 2 of a study to evaluate inhaled QBW276 in adults with CF
Status: Enrolling
Description: This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. This study will look at the safety and tolerability of the inhaled drug QBW276 as well as how the body processes the drug.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 40 to 100%
Number of Visits: 6
Length of Participation: 14 days
ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT02566044
Cohort 3 of a study to evaluate inhaled QBW276 in adults with CF
Status: Enrolling
Description: This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. This study will look at the safety, effectiveness, and tolerability of the inhaled drug QBW276.
Age: 18 Years and Older
Mutation: Two Copies F508del
Fev1% Predicted: 40 to 100%
Number of Visits: 15
Length of Participation: 3 months
ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT02566044